Abstract
To the Editor. —The review of hepatitis A prevention in travelers by Dr Steffen and colleagues 1 mentions the recently introduced vaccine based on the strain HM 175 (Havrix, SmithKline Beecham Biologicals, Rixensart, Belgium), usually administered at a dose of 720 enzyme-linked immunosorbent assay (ELISA) units. A dose of 1440 ELISA units is also mentioned. It has not been shown that a dose of 1440 units provides more protection than a dose of 720 units; published studies examining protective efficacy used 360 or 720 units. At best, the added benefit will be small. More importantly, the safety of a 1440-unit vaccine has not been adequately studied. Its use has been described in three publications. In a study by Just and Berger, 2 60 subjects received the 1440-unit vaccine and no serious adverse effects were reported. The extent of monitoring was self-reporting and liver enzyme testing. In a study by Jilg
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.